Cannabis stocks faced a precarious summer last year, but one analyst has noted that “equity markets (are) rebounding,” causing an upswing across the sector — including in Australia.

In a note sent to investors on January 22, Cameron Bell, an analyst with boutique bank Canaccord Genuity Australia, said investor confidence in the Australian cannabis market has been renewed due to an exceptionally strong recent performance from the global cannabis space.


Canaccord’s own Australian Cannabis Index has risen 34 percent over the last month, Bell said, bouncing back from the hit of over 50 percent that it took in 2019.

 

Gold Outlook 2021!

   
Gold Price Outlook, Top Stocks and More! Download today!

“The strength has been partially led by investor sentiment in offshore markets, as some key concerns have eased while expectations for demand growth remain very high and access to funding improves.”

Bell also attributed more reasonable valuations as an aid to rising share prices.

Some of the largest companies on Canaccord’s index by market cap, including EcoFibre (ASX:EOF), Elixinol Global (ASX:EXL,OTC Pink:ELLXF) and Cann Group (ASX:CAN,OTC Pink:CNGGF), have seen impressive growth in the last month.

EcoFibre is up almost 10 percent in the last month, while Elixinol and Cann Group have soared 68.9 percent and 114.7 percent, respectively, in the same span of time.

Meanwhile, Bell said patient applications through the Therapeutics Goods Association’s (TGA) Special Access Scheme-B (SAS-B) pathway were on the rise in December.

Approvals for patients increased to 3,685 application authorizations that month, up 8 percent from the 3,404 confirmations in November.

December’s numbers are also almost seven times larger year-over-year than the 490 approvals issued in December 2018, indicating a rapid rise in patient adoption for these items.

By the end of 2019, the TGA had approved over 28,000 patients throughout the year. This figure exceeded Canaccord’s expectation of 25,000 approvals, reported in a previous Australian cannabis update released in November.

Ninety percent of total SAS-B approvals have happened in the last year, Bell noted.

If growth continues at the current rate, the total number of approvals is expected to grow to 72,000 by the end of calendar 2020.

The analyst noted that there’s been an interesting shift away from the Authorised Prescribers path, which gives medical practitioners in Australia the ability to prescribe unapproved therapeutic goods, like cannabis, directly to eligible patients.

According to the TGA, there were 22 authorised prescribers in Australia at the end of December, a steep drop from the 60 reported at the end of July, Bell wrote.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

  Life Science and Healthcare Investing in 2020 report cover

Coronavirus:An Overview for Investors

 
COVID-19 continues to impact world markets. Get INN’s overview of coronavirus investing.
 

CanBud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“CanBud” or the “Corporation”) is pleased to announce that it has closed the final tranche of its oversubscribed non-brokered private placement for aggregate gross proceeds of approximately $4,730,000 (the “Offering”).

The Corporation issued a combined total of 39,409,346 units (each a “Unit“) at price of $0.12 per Unit, with each Unit comprised of one common share in the capital of the Corporation (each a “Common Share“) and one common share purchase warrant (each a “Warrant“). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.22 within 24 months of the closing of the Offering (the “Warrant Term“), provided, however that if the closing price of the Common Shares on the Canadian Securities Exchange (the “CSE“) (or any such other stock exchange in Canada as the Common Shares may trade at the applicable time) is $0.25 or greater per Common Share for a period of five (5) consecutive trading days at any time after the closing date of the Offering, the Corporation may accelerate the Warrant Term such that the Warrants shall expire on the date which is 30 days following the date a press release is issued by the Corporation announcing the reduced warrant terms.

Keep reading... Show less

Thoughtful Brands Inc. (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands) announces that the letter of intent with Franchise Cannabis Corp. (“FCC”), previously announced in January, has been terminated. The previously announced European joint venture with FCC will continue and allow the Company to launch and tailor its products to European consumer demands

In connection with termination of the merger transaction with FCC, the Company has agreed to pay FCC $100,000 in cash and to issue FCC 5,000,000 common shares of the Company at a deemed value of $0.05 per share. The common shares will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws.

Keep reading... Show less

Mergers and acquisitions (M&A) in cannabis space have helped boost the industry to new levels.

Keep reading... Show less

Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).

Keep reading... Show less

Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.

Keep reading... Show less